Nestegg Advisors Inc. purchased a new stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,643 shares of the company's stock, valued at approximately $251,000.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Fairtree Asset Management Pty Ltd purchased a new stake in Johnson & Johnson during the 4th quarter valued at about $883,000. DSG Capital Advisors LLC bought a new stake in Johnson & Johnson in the fourth quarter valued at approximately $2,888,000. Chancellor Financial Group WB LP purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $2,471,000. 111 Capital bought a new position in shares of Johnson & Johnson in the fourth quarter worth approximately $1,238,000. Finally, NorthCrest Asset Manangement LLC increased its stake in shares of Johnson & Johnson by 1.2% in the fourth quarter. NorthCrest Asset Manangement LLC now owns 235,695 shares of the company's stock worth $34,086,000 after buying an additional 2,876 shares during the period. 69.55% of the stock is owned by institutional investors.
Johnson & Johnson Stock Down 0.5%
Shares of NYSE:JNJ traded down $0.72 during midday trading on Wednesday, reaching $152.53. The company's stock had a trading volume of 8,423,290 shares, compared to its average volume of 7,953,087. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The firm has a 50 day moving average of $154.63 and a 200-day moving average of $153.64. The firm has a market capitalization of $367.00 billion, a P/E ratio of 22.94, a PEG ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. On average, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.
Johnson & Johnson Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.41%. Johnson & Johnson's payout ratio is presently 57.84%.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on JNJ shares. Morgan Stanley raised their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 16th. Benchmark raised Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Bank of America reduced their price target on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a report on Thursday, April 10th. Leerink Partnrs cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Finally, Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Eleven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $170.88.
Read Our Latest Stock Analysis on JNJ
About Johnson & Johnson
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Featured Articles
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
